Ocrelizumab is a new medication which has recently been shown in three, large phase-three clinical trials to have beneficial effects in both relapsing-remitting and primary progressive MS. When available, Ocrelizumab will be a welcome addition to the number of drugs currently licensed for relapsing-remitting MS and may also be beneficial to people with primary progressive MS.
This week, Emma Rogan reflects on the best of what makes this time of the year enjoyable. Warning, it includes many cups of tea!
Fiona O’Reilly (48) has been living with Multiple Sclerosis (MS) for the last 3 years. Some days are worse than others. Some days she can barely move at all. On others, the loss of feeling in her feet and her lack of balance put her at constant risk.
The HSE released the Service Plan for 2017 on 14th December. The Service Plan details the delivery of health services that the HSE will provide directly, and through a range of funded agencies, in 2017. The plan can be accessed here
This week Willeke Van Eeckhoutte writes about her passion and shares with us how her childhood dreams did come true.
This week Joan Jordan shares how she is *learning* to have a stress free Christmas.
© 2010 - 2025 Multiple Sclerosis Society of Ireland